Status:
COMPLETED
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Cutaneous Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to find out what patients consider when deciding whether or not to receive adjuvant treatment, and how patients feel about their decision after one year.
Eligibility Criteria
Inclusion
- Patients with stage IIIB, IIIC, IIID, or IV (AJCC, 8th edition) cutaneous melanoma rendered free of disease by surgical resection.
- Patients are being offered adjuvant nivolumab or pembrolizumab therapy
- Patient has not yet formally discussed their treatment options with their Medical Oncologist.
- Age 18 or older.
- Ability to speak and read English because we do not have the resources to translate materials into other languages.
Exclusion
- Patient not currently free of disease.
- Candidate for adjuvant dabrafenib/trametinib therapy.
- Patients who have received prior checkpoint inhibitor therapy.
Key Trial Info
Start Date :
February 14 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 29 2022
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT03843593
Start Date
February 14 2019
End Date
December 29 2022
Last Update
January 4 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
2
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, United States, 10604
3
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065